title: Reply to the letters to the editor 'Differential inﬂuence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efﬁcacy in melanoma' by Schilling et al.
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA.
authors.forename: D
authors.initials: D
authors.lastname: Davar
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA.
authors.forename: T
authors.initials: T
authors.lastname: Choi
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA kirkwoodjm@upmc.edu.
authors.forename: J M
authors.initials: JM
authors.lastname: Kirkwood